Glaxosmithkline | GSK - Operating Expenses


Glaxosmithkline reported GBP7.77B in Operating Expenses for its fiscal quarter ending in September of 2025.





Operating Expenses Change Date
AbbVie USD 10.81B 13.45B Dec/2025
Amgen USD 5.9B 773M Dec/2025
AstraZeneca USD 12.53B 4.16B Dec/2025
Aurora Cannabis CAD 146.03M 27.79M Sep/2025
Bausch Health Companies USD 2.08B 113M Dec/2025
Bristol-Myers Squibb USD 8.3B 10.25B Dec/2025
Canopy Growth CAD 80.99M 8.64M Sep/2025
Corcept Therapeutics USD 197.42M 29.66M Sep/2025
Drreddys Laboratories INR 72.94B 4.33B Dec/2025
Eli Lilly USD 10.31B 1.09B Dec/2025
GlaxoSmithKline GBP 7.18B 1.42B Dec/2025
Glaxosmithkline GBP 7.77B 2.22B Sep/2025
J&J USD 18.97B 2.38B Dec/2025
Merck USD 10.16B 558M Dec/2025
Novartis USD 9.86B 115M Sep/2025
Pacira USD 166.36M 4.5M Sep/2025
Perrigo USD 949.9M 50.8M Sep/2025
Pfizer USD 12.91B 79.89B Dec/2025
Phibro Animal Health USD 332.36M 20.68M Dec/2025
Prestige Brands USD 200.95M 6.51M Dec/2025
Roche Holding CHF 21.01B 10.84B Dec/2025
Sanofi EUR 10.51B 1.21B Dec/2025
Supernus Pharmaceuticals USD 252.29M 98.98M Sep/2025
Takeda JPY 1.02T 400.98B Dec/2025
Teva Pharmaceutical Industries USD 4.22B 812M Dec/2025
Zoetis USD 1.55B 3.85B Dec/2025